Immix Biopharma closes IPO of 4.2M shares at $5.00/share for $21M gross proceeds

Immix Biopharma, Inc.

IPO closed Dec 20, 2021; shares began trading on Nasdaq Dec 16 under IMMX.
Gross proceeds $21M; underwriters have 45-day option for up to 630K additional shares.
Net proceeds to fund IMX-110 Phase 2a trial in soft tissue sarcoma and combination trial.
Also fund IND-enabling studies for IMX-111 (colorectal cancer) and IMX-120 (inflammatory bowel disease).
Filed amended charter and bylaws in connection with IPO closing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.